Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIVDAK Ocular Assessments in Recurrent or Metastatic Cervical Cancer
NCT06952660Phase 4Recruiting
- Sponsor
- Pfizer
- Start
- May 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of tisotumab vedotin in Cervical Cancer (CC), sponsored by Pfizer. Started May 2025; status: recruiting.
02
Drugs
tisotumab vedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06952660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952660.